NCT04732416 - HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Congenital Hyperinsulinism

Interventions

DRUG

HM15136

Low dose of HM15136/ High dose of HM15136, SC injection, weekly

Trial Locations (7)

19104

RECRUITING

The Children's Hospital of Philadelphia, Philadelphia

90095

RECRUITING

University of California Los Angeles, Los Angeles

Unknown

RECRUITING

Otto-von-Guericke-Universitaet Magdeburg, Magdeburg

RECRUITING

Hadassah Medical Center (HMC), Jerusalem

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust, London

RECRUITING

Central Manchester University Hospitals NHS Foundation Trust - Royal Manchester Children's Hospital - Centre for Paediatrics and Child Health, Manchester